John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 38 years experience in U.S. FDA-regulated industries, 24 as an independent consultant. John has worked with companies from start-up to Fortune 100, world wide. He specializes in quality assuranc Read more
FDA Warning Letters and recent high-profile recalls indicate major cGMP deficiencies in many companies. One major failing is lack of sufficient or targeted risk-based company-wide V&V planning.
Starting with a Master Validation Plan, evaluating its elements against ISO 14971 hazard analysis / risk management, allows development of meaningful product validations. The roles of different V&V protocols. How to employ equipment / process DQs, IQs, OQs, and PQs, or their equivalents per ASTM E2500, against a background of limited company resources (personnel, budget, time). A matrix simplifies “as-product”, “in-product”, process, and equipment, et al, software V&VT, assuring key FDA requirements are not overlooked. The QMS and 21 CFR Part 11 must also be considered.
Why Should You Attend:
Verification and validation requirements have always been part of the US FDA’s GMPs. However, with increasing technology, both industry and regulatory agencies expectations have increased.
Recent high-profile field problems indicate that V&V activities are not planned or carried out as completely as expected, are not documented in a top tier Master Validation Plan, and may not be fully utilizing the power of current risk management tools, as identified in ISO 14971. The FDA / ICH Q-series provide valuable insights for all regulated industries, not just pharma. The billions of dollars spent by industry annually for V&V are not providing the product safety or efficacy seemingly promised. For most companies, the fixes are not rocket-science, but proper up-front V&V planning and execution, documented in a corporate MVP and implemented by other V&V documents.
Course Outline:
• Verification or Validation – Recent regulatory expectations
• The Master Validation Plan and its structure
• Product Validation – how it differs from process / equipment V&V
• Process / Equipment / Facility Validation – including FDA’s recent guidance
• When and How to use DQ, IQ, OQ, PQ, or their equivalents
• How to use Product Risk Management Tools (per ISO 14971 and ICH Q9)
• The 11 key documents for software validation
• Incorporating 21 CFR Part 11 requirements
• Suggested “test case” formats
What You Get:
• Training Materials
• Live Q&A Session with our Expert
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
• Quality Departments
• Regulatory Affairs Departments
• R&D Departments
• Engineering Departments
• Production Departments
• Operations Departments
• Consultants
Write it Right – Well Written Procedures are Essential for QMS Effectiveness
LIVE : Scheduled on
17-January-2025 :01:00 PM EST
|
FDA Audit Best Practices - Dos and Don'ts
LIVE : Scheduled on
24-January-2025 :01:00 PM EST
|